Asteria Health recalled 1,631 sterile pellets of Testosterone and Triamcinolone Acetonide on January 26, 2026, due to potential metal contamination. Consumers should stop using the product immediately. This recall affects products distributed nationwide in the USA.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The testosterone and triamcinolone pellet is a medication used for hormone therapy, often prescribed for testosterone replacement. Consumers typically purchase this product for managing low testosterone levels or related health issues.
The presence of metal particulate matter in the pellets could lead to serious health complications if ingested. This contamination can occur during manufacturing or packaging, underscoring the need for immediate action.
This recall is not part of a broader industry pattern.
Consumers face potential health risks from using the contaminated product, and they must take immediate steps to stop use and seek guidance.
The lot number and expiration date are typically found on the product label or packaging.
Expect a refund or replacement to be processed within 4-6 weeks after returning the product.
Keep a record of your purchase, return correspondence, and any communications with the manufacturer.
The recall involves Testosterone 87.5mg and Triamcinolone Acetonide 17.5 mcg in a single sterile pellet. The affected lot number is 256000103, with an expiration date of July 28, 2026. The product was distributed nationwide.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Asteria Health recalled 60,868 testosterone pellets on January 26, 2026, due to contamination risks. The recall affects specific lots of the product that may contain metal particulate matter. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,015 testosterone pellets on January 26, 2026 due to potential metal particulate contamination. The recall affects products distributed nationwide in the United States. Consumers must stop using the pellets immediately and contact their healthcare provider for guidance.
Asteria Health recalled 89,074 testosterone pellets on January 26, 2026. The recall stems from potential metal particulate contamination. Consumers must stop using the product and contact their healthcare provider immediately.
Asteria Health recalled 22,478 Estradiol 12.5 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The FDA classified this recall as Class II, indicating a high hazard level.
Asteria Health recalled 24,099 Estradiol, 10 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 50,990 Estradiol pellets on January 26, 2026, due to potential metal particulate matter contamination. The recall affects products distributed nationwide in the USA. Consumers should stop using the pellets immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.